Our results also indicated lower fetuin-A expression levels in plasma from patients with B-ALL in comparison with those of healthy controls via both the proteomic and ELISA approaches, which further indicates the potential of fetuin-A as a possible tumor marker. The gene discussed is AHSG; the disease is neoplasm.